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Abstract
In the past decades liver transplantation (LT) has 
become the treatment of choice for patients with 
end stage liver disease (ESLD). The chronic shortage 
of cadaveric organs for transplantation led to the 
utilization of a greater number of marginal donors such 
as older donors or donors after circulatory death (DCD). 
The improved survival of transplanted patients has 
increased the frequency of long-term complications, in 
particular chronic kidney disease (CKD). Acute kidney 
injury (AKI) post-LT has been recently recognized 
as an important risk factor for the occurrence of de 
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novo CKD in the long-term outcome. The onset of 
AKI post-LT is multifactorial, with pre-LT risk factors 
involved, including higher Model for End-stage Liver 
Disease score, more sever ESLD and pre-existing renal 
dysfunction, either with intra-operative conditions, in 
particular ischaemia reperfusion injury responsible for 
post-reperfusion syndrome (PRS) that can influence 
recipient’s morbidity and mortality. Post-reperfusion 
syndrome-induced AKI is an important complication 
post-LT that characterizes kidney involvement caused 
by PRS with mechanisms not clearly understood and 
implication on graft and patient survival. Since pre-
LT risk factors may influence intra-operative events 
responsible for PRS-induced AKI, we aim to consider 
all the relevant aspects involved in PRS-induced AKI 
in the setting of LT and to identify all studies that 
better clarified the specific mechanisms linking PRS 
and AKI. A PubMed search was conducted using the 
terms liver transplantation AND acute kidney injury; 
liver transplantation AND post-reperfusion syndrome; 
acute kidney injury AND post-reperfusion syndrome; 
acute kidney injury AND DCD AND liver transplantation. 
Five hundred seventy four articles were retrieved on 
PubMed search. Results were limited to title/abstract 
of English-language articles published between 2000 
and 2015. Twenty-three studies were identified that 
specifically evaluated incidence, risk factors and 
outcome for patients developing PRS-induced AKI in 
liver transplantation. In order to identify intra-operative 
risk factors/mechanisms specifically involved in PRS-
induced AKI, avoiding confounding factors, we have 
limited our study to “acute kidney injury AND DCD AND 
liver transplantation”. Accordingly, three out of five 
studies were selected for our purpose.
Key words: Liver transplantation; Acute kidney injury; 
Post-reperfusion syndrome; Donation after circulatory 
death; Chronic kidney disease
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Core tip: Post-reperfusion syndrome (PRS)-induced 
acute kidney injury (AKI) has been recognized as 
an important complication occurring after liver trans-
plantation (LT) that characterizes kidney involvement 
caused by PRS with mechanisms not clearly understood 
and implication on graft and patient survival. Since pre-
LT risk factors may influence intra-operative events 
responsible for post-reperfusion syndrome-induced AKI 
(PRS-induced AKI), we aim to consider all the relevant 
aspects involved in PRS-induced AKI in the setting of 
LT and to identify all studies that better clarified the 
specific mechanisms linking PRS and AKI, in particular 
in LT recipients from donation after circulatory death.
Umbro I, Tinti F, Scalera I, Evison F, Gunson B, Sharif A, 
Ferguson J, Muiesan P, Mitterhofer AP. Acute kidney injury 
and post-reperfusion syndrome in liver transplantation. World J 
Gastroenterol 2016; 22(42): 9314-9323  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i42/9314.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i42.9314
INTRODUCTION
Liver transplantation (LT) is the treatment of choice 
for patients with end stage liver disease (ESLD). 
Ongoing progress in organ preservation, surgical 
and anaesthetic techniques and immunosuppression 
has improved outcomes with 1-year survival > 85% 
and 5-year survival > 75%. The chronic shortage 
of cadaveric organs for transplantation led to the 
utilization of a greater number of marginal donors such 
as older donors or donors deceased after circulatory 
death (DCD). The improved survival of transplanted 
patients has increased the frequency of long-term 
complications, in particular chronic kidney disease 
(CKD). The incidence of CKD at 10 years after LT 
can be as high as 28%[1] leading to 4-fold increase in 
mortality[1,2].
Acute kidney injury (AKI) post-LT has been recently 
recognized as an important risk factor for the occurrence 
of de novo CKD in the long-term follow up after LT[3].
Risk factors for AKI may be related to pre-LT 
conditions, such as severe ESLD, higher model for 
end-stage liver disease (MELD) score and pre-existing 
renal dysfunction, either to intra-operative conditions, 
in particular ischaemia reperfusion injury (IRI)[4-6]. The 
latter is responsible for the post-reperfusion syndrome 
(PRS), which is an intra-operative complication, whose 
definition is still under debate, that may influence 
morbidity and mortality of recipients. PRS involves 
intra-operative events such as reduction of mean 
arterial pressure (MAP), presence of haemodynamic 
arrhythmias, need for inotropic drugs during transplan-
tation[7]. This condition promotes multi-organ damage, 
with particular kidney involvement through systemic 
inflammatory and haemodynamic mechanisms in 
addition to a direct damage with tubular cell death. 
Post-reperfusion syndrome-induced AKI (PRS-induced 
AKI) is an important complication post-LT that cha-
racterizes kidney involvement caused by PRS with 
mechanisms not clearly understood and implication on 
graft and patient survival.
Furthermore, after LT period, graft dysfunction, 
reoperation, bacterial infection, sepsis and acute CNIs 
toxicity may be associated to renal dysfunction[8-12].
Since pre-LT risk factors may influence intra-
operative events responsible for PRS-induced AKI, we 
aim to consider all the relevant aspects involved in 
PRS-induced AKI in the setting of LT and to identify all 
studies that find out the specific mechanisms linking 
PRS and AKI.
LITERATURE SEARCH
A PubMed search was conducted using the terms 
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liver transplantation AND acute kidney injury; liver 
transplantation AND post-reperfusion syndrome; acute 
kidney injury AND post-reperfusion syndrome; acute 
kidney injury AND DCD AND liver transplantation. 
Five hundred seventy four articles were retrieved on 
PubMed search. Results were limited to title/abstract 
articles published in English between 2000 and 2015; 
studies on children, case reports, editorials and review 
articles were not considered. We have identified twenty-
three papers that specifically evaluated incidence, 
risk factors and outcome for patients developing PRS-
induced AKI in LT.
In order to identify intra-operative risk factors/
mechanisms specifically involved in PRS-induced 
AKI, avoiding confounding factors, we have limited 
our study to “acute kidney injury AND DCD AND liver 
transplantation”. Accordingly, three out of five studies 
were selected for our purpose (Table 1).
ACUTE KIDNEY INJURY POST-LT
Acute kidney injury is a significant complication after 
LT. It is reported to be associated to an increased 
mortality[13,14] and to the development of CKD after 
LT[15]. Recently, reversible AKI has been recognised as 
an important risk factor for de novo CKD in the non-
transplant setting, suggesting important implications 
also for the surveillance in patients without pre-existing 
and clinically evident kidney disease[16].
The incidence of post-operative AKI in the setting 
of LT ranges between 12% and 80%, depending on 
the definition adopted[17,18], with a 30-d mortality of up 
to 50% in case of renal dysfunction at transplantation 
and as high as 90% if renal replacement therapy (RRT) 
is required[4,19].
Different criteria have been used to diagnose and 
classify AKI. A recent new definition of AKI has been 
proposed on the basis of the universal consensus of 
KDIGO criteria, which are an evolution of RIFLE and 
AKIN criteria[20,21].
Moreover, since all risk factors for AKI in the setting 
of LT are intertwined between the pre-LT and the intra-
operative period, we should consider all risk factors in 
order to evaluate the PRS-induced AKI.
PRE-TRANSPLANT RISK FACTORS FOR 
POST-LT PRS-INDUCED AKI 
MELD
MELD score was created to predict poor survival in 
patients with liver cirrhosis and portal hypertension 
complications, undergoing elective transjugular 
intrahepatic porto-systemic shunts placement[22]. 
The formula for calculation of MELD includes only 3 
objective parameters [serum creatinine (sCr), serum 
bilirubin and INR]; it was validated by the Organ 
Procurement and Transplantation Network in 2002 as 
an accurate predictor of poor survival in patients with 
various stages of liver disease, as well as in patients of 
different geographic origin[23]. The main use of MELD 
score is regarded to liver graft allocation, identifying 
those patients in greater immediate need for LT[24], 
and in predicting outcome and survival post-LT[25,26]. 
Pre-operative sCr was identified as an independent 
predictor of post-transplant mortality before the 
introduction of MELD score[27].
Other factors affect sCr, such as gender. It is 
reported that women are disadvantaged in MELD era 
possibly due to the inclusion of sCr. Women are less 
likely than men to receive a LT and have greater 3-mo 
mortality, probably due to low sCr and MELD compared 
to men. However within most MELD strata, women 
had more deranged serum bilirubin and INR[28].
End stage liver disease
In advanced cirrhosis, the systemic vascular resistance 
is particularly decreased, and any additional increase 
in cardiac output can no longer compensate, leading to 
under filling of arterial circulation[29]. In this scenario, 
systemic arterial pressure and effective arterial blood 
volume are maintained through the activation of 
vasoconstrictor systems, including renin-angiotensin-
aldosterone system (RAAS), sympathetic nervous 
system, and, later, non-osmotic hyper-secretion of 
antidiuretic hormone. This leads to sodium and solute-
free water retention and renal failure due to intra-renal 
vasoconstriction and hypoperfusion[29].
Recently, a new specific form, named acute-
on-chronic liver failure has been recognised to be 
associated to high risk for short-term mortality in 
advanced ESLD. This syndrome is defined as an acute 
decompensation of cirrhosis (development of ascites, 
bacterial infections, gastrointestinal hemorrhage and/
or encephalopathy) associated to organ failure (liver, 
kidney, coagulation, circulation, respiration, brain) and 
high short-term mortality, ≥ 15% within a period of 28 
d[30]. The type of organ failure is obviously a risk factor 
for mortality and it is > 15% in patients with kidney 
failure compared to < 15% for single non-kidney organ 
failures[31].
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Table 1  Summary of studies evaluating acute kidney injury in 
donors after circulatory death liver transplant recipients
Study Journal and Year Outcome Diagnosis
Doyle et al[96] J Am Coll Surg 2015 AKI RRT
Ruebner et al[95] Transpl Int 2014 End stage renal 
disease
Leithead et al[112] J Hepatol 2014 AKI KDIGO 
criteria
Elaffandi et al[113] Liver Transpl 2014 Prehospital 
cardiac arrest
Leithead et al[99] Am J Transplant 2012 AKI RIFLE 
classification
AKI: Acute kidney injury; RRT: Renal replacement therapy; KDIGO: 
Kidney disease improving global outcomes; RIFLE: Risk, injury, failure, 
loss of kidney function, and end-stage kidney disease.
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result of an underestimation of glomerular filtration rate 
(GFR). Therefore, the evaluation of sCr modifications 
from baseline is the best way to assess renal function 
in patients with ESLD[8].
Since the multiple limitations of sCr as a measure 
of renal function in these patients, alternative methods 
were proposed such as GFR estimation by inulin clea-
rance[52]. This is the gold standard for renal function 
assessment but its routinely use is limited due to 
high cost and technical difficulties[52]. Other direct 
methods are characterized by the use of exogenous 
radiolabelled substances or non-radioactive agents[53]. 
Nevertheless they have not been widely confirmed in 
patients with ESLD. Furthermore, creatinine clearance 
is not better than sCr in evaluating renal function in 
patients with cirrhosis due to several variables including 
potential errors in collection and measurement of urine, 
variations in re-absorption or excretion of creatinine 
and sCr dilution caused by fluid retention[54].
Serum cystatin C is freely filtered by glomeruli 
and then re-absorbed and catabolized by proximal 
tubules[55]. For this reason, it is recognised as a 
sensitive indicator of renal function in liver cirrhosis[56,57], 
significantly different from inulin or exogenous radio-
labelled substances[58,59]. However, further studies 
are needed to develop specific cystatin C-based GFR 
estimation formulas in patients with ESLD.
Nevertheless, sCr remains the clinical marker of 
kidney function for routinely practice, and changes in 
sCr are currently used specifically to define AKI.
Therefore, in order to standardize its definition, the 
classification of AKI was recently revised by KDIGO 
group including all causes of acute renal dysfunction as 
indicated by an increase in sCr to 1.5-1.9 times from 
baseline within 7 d or an increase in sCr by ≥ 26.5 
mmol/L (≥ 0.3 mg/dL) in < 48 h, allowing patients 
with less severe degrees of renal dysfunction to receive 
treatment[60].
Pre-existing renal disease
Kidney failure among patients with ESLD is closely 
related to liver disease severity. This is due to circulatory 
disturbances characterized by reduced systemic 
vascular resistance secondary to splanchnic arterial 
vasodilatation due to portal hypertension[29,61].
Hepatic and renal disorders are frequently associated 
as a result of a number of systemic conditions that 
concurrently affect liver and kidney. Furthermore, renal 
dysfunction is also a common complication of primary 
liver disorders with renal histological changes mainly of 
glomerular type, named hepatic glomerulosclerosis. It 
was initially described predominantly in patients with 
advanced liver cirrhosis and recently in HCV-related 
cirrhosis[62,63]. This is characterised by mesangial 
expansion, thickening of capillary walls, a mild increase 
in size and number of endothelial and epithelial cells, 
and deposits of immunoglobulins and electron-dense 
material in the mesangium and capillary walls[63,64], 
The aetiology of ESLD in some cases seems to 
be involved in the occurrence of AKI. Non-alcoholic 
steatohepatitis (NASH), now regarded as the hepatic 
manifestation of the metabolic syndrome[32-34], was 
found to be more frequently associated with post-LT 
AKI compared to other liver diseases leading to ESLD. 
This association is not surprising, since the increasing 
prevalence of NASH and non-alcoholic fatty liver 
disease (NAFLD) contributes to hyperlipidaemia and 
diabetes.
Clear evidences suggest the existence of a link 
between NAFLD/NASH and renal impairment. Different 
mechanisms have been hypothesized, involving multiple 
pro-inflammatory substances that originate in the 
steatotic and inflamed liver or through the contribution 
of systemic insulin resistance and atherogenic dys-
lipidemia[35].
Patients with NAFLD have significantly low levels 
of adiponectin, higher levels of hemostatic and 
inflammatory factors, oxidative stress and endothelial 
dysfunction biomarkers[34,36-39]. Similarly, patients with 
renal disease showed reduced adiponectin levels, 
as well as increased levels of oxidative stress and 
systemic inflammation biomarkers, hypofibrinolysis 
and hypercoagulation[40-43]. The supposed mechanisms 
that link NAFLD and renal disease may begin from the 
inflamed and expanded visceral adipose tissue that 
releases multiple molecules, such as free fatty acids, 
hormones, tumor necrosis factor-alpha, interleukin-6, 
and other pro-inflammatory cytokines, that seem 
to be implicated in the insulin resistance and kidney 
damage[44,45]. In this context, the liver is both source 
of several mediators and target of these systemic 
abnormalities, amplifying kidney damage. Even 
though the mechanisms by which oxidative stress 
and chronic inflammation can damage kidney are not 
completely described, some studies on animal models 
showed that cytokine imbalance may have a role in 
the pathogenesis of kidney involvement through the 
activation of different pro-inflammatory pathways, up-
regulation of adhesion molecules, induction of oxidative 
stress and endothelial dysfunction, as well as reduction 
of adiponectin expression[43,46-49]. As a result, patients 
with NAFLD should be considered at increased risk 
for the occurrence of pre-transplant renal disease[35]. 
Furthermore, macrovescicular steatosis was described 
as a risk factor for PRS by Chung et al[50].
Evaluation of renal function
The evaluation of renal function in patients with ESLD 
waiting for LT remains a challenge. Serum creatinine 
may be influenced by several factors including age, 
race, gender, body weight, medications, diet and 
laboratory techniques. In the context of cirrhosis, 
sCr can be affected by reduced hepatic production of 
creatine (> 40%), protein malnutrition, decreased 
muscle mass, oedema and increased tubular secretion 
of creatinine[51]. As a result, low levels of sCr are the 
Umbro I et al . AKI and PRS in liver transplantation
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as demonstrated in renal biopsies performed at the 
time of LT[63,65]. Recently, trans-jugular renal biopsies 
performed in cirrhotic patients with clotting problems 
showed an incidence > 70% of glomerular lesions with 
a prevalence of IgA deposition[66].
In advanced cirrhosis, renal dysfunction results 
mainly from renal hypoperfusion due to intravascular 
volume depletion secondary to diuretic use, lactulose-
induced diarrhoea, gastrointestinal bleeding, infections, 
use of nephrotoxic agents such as nonsteroidal anti-
inflammatory drugs, contrast agents, and amino-
glycosides. Intense renal vasoconstriction, as seen 
during hepatorenal syndrome, can in turn lead to renal 
tubular necrosis. The histological changes are very 
similar to those reported for chronic nephrotoxicity 
from calcineurin inhibitors and differential diagnosis 
may be difficult[61,67-69].
Hepatitis B virus-related cirrhosis is associated with 
membranous glomerulonephritis (GN) and membrano-
prolipherative GN, but also with vasculitis, such as 
polyarteritis nodosa[70]. Hepatitis C virus-related cirrhosis 
is associated primarily with membrano-prolipherative 
GN and cryoglobulinaemia, but also with fibrillary 
GN[71,72]. In addition, the occurrence of type 2 diabetes 
mellitus in HCV-infected patients is associated with 
earlier loss of renal function compared with uninfected 
patients[73]. Alcoholic cirrhosis is linked mainly with 
IgA nephropathy[74]. Primary sclerosing cholangitis 
and primary biliary cirrhosis are associated with anti-
neutrophil cytoplasmic autoantibody-positive vasculitis 
and membranous nephropathy[74,75].
A few primary diseases can affect both liver and 
kidney, including polycystic disease, primary oxaluria, 
alpha1-antitrypsin deficiency and Wilson’s disease. A 
secondary involvement of the kidney may result such 
as in diabetic nephropathy.
In literature it is increasingly reported a close 
association between renal failure and severe liver 
dysfunction in patients with ESLD[76-79]. In the setting 
of LT the interval of pre-transplant renal dysfunction is 
predictive of 6- and 12-mo sCr post-transplant[80].
MELD score, ESLD, pre-existing Renal Disease and 
PRS-induced AKI
Recipient characteristics including older recipient age[81], 
higher MELD score, sCr levels[82], bilirubin and higher 
pre-operative heart rate[50] seem to have a role in the 
development of PRS. This may reflect the occurrence 
of haemodynamic and cardiovascular complications 
that characterise patients with cirrhosis[83]. These 
patients develop splanchnic arteriolar vasodilatation, 
leading to reductions of systemic vascular resistance, 
central volume, and arterial filling. The activation 
of RAAS and sympathetic nervous system, and the 
release of vasopressin all contribute to maintain the 
arterial blood pressure, thus inducing a hyperdynamic 
circulatory state[83]. The progression of cirrhosis leads 
to more pronounced splanchnic vasodilatation with 
failure of the hyperdynamic compensation, lower 
systemic vascular resistance index, higher cardiac 
output, and decreased arterial blood pressure[83,84]. The 
state of advanced cirrhosis is in line with the higher 
MELD score and the more pronounced haemodynamic 
changes with the occurrence of renal dysfunction.
The loss of integrity of the vasoconstrictive response 
during graft reperfusion is also believed to be, at least 
partially, responsible for the development PRS[85,86].
In an experimental model of rats with portal hy-
pertension the pressor response generated by the 
sympathetic system was found to be impaired[87]. 
Similarly, the peripheral vascular response to angiotensin 
Ⅱ and noradrenaline is attenuated in patients with 
liver cirrhosis[88,89]. Garutti Martinez et al[85] reported a 
lower increase in vascular muscle tone reflected by an 
increased systemic vascular resistance index in patients 
experiencing PRS, suggesting a reduced vascular 
adaptability in these patients. A significant reduction 
in sympathetic tone has also been reported in patients 
who developed PRS[86]. Although altered cardiovascular 
autonomic control may not clarify the reason for the 
occurrence of graft reperfusion-related hypotension 
during LT, the assessment of autonomic indices may 
be helpful in predicting PRS occurrence and may 
help anaesthesiologist management in preventive 
treatment with vasoconstrictors before any substantial 
decrease in MAP in the first minutes after reperfusion.
Left ventricular diastolic dysfunction was found 
to be a risk factor for the development of PRS in a 
Chinese population of liver transplanted patients by 
Xu et al[90]. Diastolic dysfunction has been entitled as 
cause of perioperative haemodynamic instability and 
an adverse outcome following cardiac surgery[91] and 
may contribute to the development of PRS by inducing 
haemodynamic instability during LT.
SPECIFIC INTRA-OPERATIVE RISK 
FACTORS FOR POST-LT PRS-INDUCED 
AKI
PRS
PRS is an intra-operative complication that chara-
cterizes specific surgical phases related to instability 
at reperfusion involving cardiovascular and metabolic 
alterations, together with a PRS-induced AKI, that 
can influence recipient’s morbidity and mortality. 
Pathophysiology of PRS has not been clarified 
yet; several mechanisms have been hypothesized, 
considering factors related to recipient or donor 
characteristics, graft quality and intra-operative factors.
Donors deceased after circulatory death characterized 
by prolonged ischaemic phase of the graft compared 
to traditional brain death donors. Although LT from 
DCD donors demonstrates satisfactory long-term 
outcomes, these are burdened by a higher degree 
of delayed graft function compared to donation after 
brain death (DBD) and a higher frequency of AKI 
as well as CKD[92-95], despite similar pre-LT renal 
Umbro I et al . AKI and PRS in liver transplantation
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function[96]. In this setting, the damage sustained by 
the graft during cold preservation following recovery 
from the donor and during subsequent warm at 
implantation into the recipient[97] is intensified by the 
period of warm ischaemia in the donor. The functional 
donor warm ischemic time (dWIT) is defined as the 
interval between hypotension (Systolic Blood Pressure 
< 50 mmHg) or hypoxia (02 saturations < 70%) and 
cold perfusion of the aorta[98]. Functional dWIT adds 
complementary injury to cold ischaemia. Elevation of 
serum aminotransferase enzymes is the first clinical 
evidence of IRI of the graft, which can lead up to 
clinical liver dysfunction and progressive graft failure. 
In a study by Leithead et al[99] on AKI in DCD LT, the 
only consistent predictor of renal outcomes was peak 
peri-operative aspartate aminotransferase, which 
represents a surrogate marker of hepatic IRI. The 
hepatic IRI is known to evoke a systemic inflammatory 
response, which can cause distant organ dysfunction 
and AKI through haemodynamic mechanisms and 
direct tubular cell death, associated to PRS[23,100-103]. 
Therefore, graft injury, by driving a systemic inflam-
matory response, may be a contributing factor of PRS-
induced AKI.
Furthermore, in the same single-centre case-
controlled study it has been shown for the first 
time that LT from DCD donors was associated with 
higher incidence of AKI and RRT, evaluated by RIFLE 
criteria, compared to propensity score-matched DBD 
recipients, despite a significant (53.4% vs 31.8%, P = 
0.004) better renal function in DCD vs DBD[99].
Donor and graft characteristics
Cold ischaemia time (CIT) and graft steatosis have 
been reported to be associated with PRS in several 
studies[6,13,17,21,22]. The increased CIT is likely to increase 
the IRI which is associated with release of increased 
amounts of pro-inflammatory mediators, generation of 
free radicals, neutrophil sequestration and activation[50]. 
Steatotic livers tolerate less the IRI and it is conceivable 
that the higher percentage of steatosis is linked to a 
higher degree of damage. The release of vasoactive 
substances, including reactive oxygen species[32], pro-
inflammatory chemokines and cytokines[33], from 
the transplanted liver is also considered as a possible 
mechanism of PRS.
An important link between IRI and PRS is similarly 
accounted by Pan et al[104] in their retrospective study, 
where they report a double incidence of PRS in DCD 
compared to DBD (25.7% vs 12.2%, respectively). 
These authors also suggest that the severe IRI 
experienced by DCD grafts during the additional warm 
ischaemia occurring before organ procurement may 
play a role in the development of PRS.
Donor age and donor risk index (DRI) are also 
reported being associated with the development of 
PRS[105] and with greater haemodynamic instability 
and delayed intra-operative haemodynamic recovery. 
A role for poor tolerance of ischemia-reperfusion 
phenomenon or age-related steatotic parenchymal 
changes (senescence) has been advocated[105].
Intra-operative factors
Intra-operative events additionally play a role in 
transfusion requirements[50,81,106]. These are associated 
to the severity of liver disease, characterized by anaemia 
and coagulation abnormalities. Intra-operative blood 
loss thereby increases, requiring transfusion of blood 
products, which itself is linked to fibrinolysis associated 
with severe PRS[81,106].
The use of piggy-back technique and porto-caval 
shunt seems to reduce the occurrence of PRS[107,108]. 
The piggy-back technique is proven to provide better 
haemodynamic stability and the severity of PRS has 
been associated to the surgical technique utilised. 
Currently, piggy-back technique is widely used making 
difficult to clearly ascertain the role of operation 
technique as a risk factor[108].
Otherwise the preservation of caval flow does not 
prevent hypotension during graft reperfusion[109]. The 
creation of a temporary portocaval shunt in patients 
with cirrhosis during the anhepatic phase, reducing 
splanchnic congestion, in theory limits splanchnic 
ischaemia and the subsequent release of toxic 
mediators at reperfusion[110]. This hypothesis may in 
part account for the protective effect of a portocaval 
shunt toward the incidence of intra-operative PRS[107].
The need for emergent and unplanned intra-
operative RRT (IORRT) during LT is associated with a 
greater incidence of PRS compared to both patients 
not receiving IORRT and patients receiving planned 
IORRT[111]. IORRT become part of a complex multi-
factorial cause of reduced patients short-term survival. 
A role has been advocated for planned IORRT to 
correct metabolic derangements due to electrolyte and 
acid/base disturbances occurring in patients with pre-
transplant renal failure[111].
CONCLUSION
Although advances in medical and surgical techni-
ques have been done to improve survival among LT 
recipients, mortality rates related to post-LT renal 
complications remain a concern. The onset of AKI post-
LT is multifactorial, with pre-LT risk factors involved, 
including higher MELD score, ESLD and pre-existing 
renal dysfunction, either with intra-operative conditions 
such as IRI and PRS. Recently, PRS-induced AKI is 
considered an important complication post-LT that 
characterizes kidney involvement caused by PRS with 
mechanisms not clearly understood and implication on 
graft and patient survival. Pre-LT risk factors for AKI 
and PRS are closely intertwined and the impact of PRS-
induced AKI on the onset of long-term CKD is very 
important. Furthermore, a strong influence of donor 
quality has also been described on the development 
of CKD post-LT[95]. Receiving a liver from DCD or with 
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higher DRI increase the risk of end-stage renal disease 
by 40%, despite favourable recipient characteristics, 
supporting the current knowledge that donor quality 
is associated with short and long-term outcomes, 
renal injury in particular[95]. The better understanding 
of predisposing factors for post-LT AKI may give the 
possibility to improve methods to prevent or ameliorate 
injury. Therefore, this new understanding may possibly 
help researchers to develop further studies in order to 
better clarify PRS and PRS-induced AKI, in particular in 
DCD recipients.
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